Last mentioned: Mar 10, 2026
Potential Approval
Estimated decision date if the FDA grants a 6-month priority review.
FDA Filing Deadline
Target date for completing the accelerated approval application with the FDA.
Phase 3 Success
Vertex reports povetacicept met primary goals in late-stage IgA nephropathy trial.
Alpine Acquisition
Vertex announces $4.9 billion acquisition of Alpine Immune Sciences to gain povetacicept.
Vertex Pharmaceuticals reported that its lead kidney drug candidate, povetacicept, achieved a 52% reduction in proteinuria in a late-stage trial for IgA nephropathy. The success validates Vertex's $4.9 billion acquisition of Alpine Immune Sciences and marks a significant step in its strategy to diversify beyond cystic fibrosis.
This page surfaces every story mentioning Alpine Immune Sciences Inc. across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Alpine Immune Sciences Inc. was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |